
TScan Therapeutics (TCRX) Stock Forecast & Price Target
TScan Therapeutics (TCRX) Analyst Ratings
Bulls say
TScan Therapeutics is supported by encouraging Cohort C clinical data, as all 13 patients achieved complete donor chimerism by August 27th, including two previously relapsed patients who responded after a third dose of TSC-101 and/or maintenance therapy. The 6-month relapse rate of about 20% in 14 patients, most of whom were MRD+, compares favorably with historic relapse rates of roughly 45% in MRD+ and 20% in MRD- patients after HSCT, strengthening the case that its TCR-T approach may meaningfully reduce post-transplant relapse risk. With an update planned for ASH in 4Q:26 and a ≥1-year update for all patients, including the 7 patients from ALLOHA-2, in 2Q:27, the company has multiple upcoming catalysts that could validate the durability of its program.
Bears say
TScan Therapeutics is facing a thesis-breaking shift because management paused its most advanced asset, TSC-101 in ALLOHA-2, despite encouraging Cohort C data and complete donor chimerism, removing the main clinical and valuation driver. The company is now reliant on two preclinical in vivo TCR-T programs targeting PRAME and MAGE-A4, with first IND expectations in 3Q27 and Phase 1 not planned until 4Q27, while the 75% workforce reduction and elimination of internal manufacturing only extend runway to 4Q27. Although the restructuring is expected to create about $55M of cumulative savings and leave $100M of 2Q:26 cash to fund operations into 4Q27, the stock remains burdened by financing risk, partnership dependence, and limited visibility that the new platform can generate near-term value.
This aggregate rating is based on analysts' research of TScan Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
TScan Therapeutics (TCRX) Analyst Forecast & Price Prediction
Start investing in TScan Therapeutics (TCRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About TScan Therapeutics (TCRX) Forecast
TScan Therapeutics (TCRX) Analyst Forecast & Price Prediction
Start investing in TScan Therapeutics (TCRX)
Order type
Buy in
Order amount
Est. shares
0 shares